The Clinical Efficacy and Safety of SGLT2 Inhibitors in Japanese Patients with Type 2 Diabetes for Two Years

被引：0
|
作者：
Tosaki, Takahiro
Kamiya, Hideki
Inagaki, Akemi
Kondo, Masaki
Nagao, Eriko
Yamada, Yuichiro
Kato, Yoshiro
Tsunekawa, Shin
Himeno, Tatsuhito
Hayasaki, Tomoyo
Sato, Shiori
Nakaya, Yuki
Nakamura, Jiro
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2420-PUB
引用
收藏
页码：A631 / A631
页数：1
相关论文
共 50 条
  • [41] SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
    Thomas, Merlin C.
    Neuen, Brendon L.
    Twigg, Stephen M.
    Cooper, Mark E.
    Badve, Sunil, V
    ENDOCRINE CONNECTIONS, 2023, 12 (08)
  • [42] Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
    Fujiwara, Makoto
    Shimizu, Masaru
    Maejima, Yuko
    Shimomura, Kenju
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [43] Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
    Makoto Fujiwara
    Masaru Shimizu
    Yuko Maejima
    Kenju Shimomura
    BMC Research Notes, 15
  • [44] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [45] Verification of the efficacy and safety of tofogliflozin, a novel SGLT2 inhibitor, in Japanese patients with type 2 diabetes mellitus: results from a phase 2/3 clinical study
    Araki, E.
    Kaku, K.
    Watada, H.
    Iwamoto, Y.
    Utsunomiya, K.
    Terauchi, Y.
    Tobe, K.
    Tanizawa, Y.
    DIABETOLOGIA, 2013, 56 : S371 - S371
  • [46] Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
    de la Flor, Jose C.
    Villa, Daniel
    Cruzado, Leonidas
    Apaza, Jacqueline
    Valga, Francisco
    Zamora, Rocio
    Marschall, Alexander
    Cieza, Michael
    Deira, Javier
    Rodeles, Miguel
    BIOMEDICINES, 2023, 11 (07)
  • [47] Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion
    Hattersley, Andrew T.
    Thorens, Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (10): : 974 - 976
  • [48] Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes
    Corral, Pablo
    Nardelli, Natalia
    Elbert, Alicia
    Aranguren, Florencia
    Schreier, Laura
    CURRENT DIABETES REPORTS, 2025, 25 (01)
  • [49] SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
    Saisho, Yoshifumi
    DISEASES, 2020, 8 (02)
  • [50] Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
    Muskiet, Marcel H. A.
    van Bommel, Erik J. M.
    van Raalte, Daniel H.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 188 - 189
12345